RAD June 2021 Virtual Conference Abstracts & Posters
Abstracts have been published in the September 2021 issue of the British Journal of Dermatology and can be found here: https://onlinelibrary.wiley.com/doi/10.1111/bjd.20648.#490 - Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Combined Safety Analysis of Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Emma Guttman-Yassky, MD; Alan D Irvine, MD; Jonathan I Silverberg, MD, PhD, MPH; Kim A Papp, MD; Amy S Paller, MD; Brian Waterhouse, MS; Allan R Tenorio, MD; Barry Ladizinski MPH, MBA; Alvina D Chu, MD; John Liu, MD, MS; Kristian Reich, MD, PhD
#491 - Effects of Upadacitinib on the Patient-Reported Impact of Atopic Dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) Results From Two Pivotal Phase 3 Studies (MEASURE UP 1 and MEASURE UP 2)
Eric L. Simpson, Marjolein S. de Bruin-Weller, Vimal H. Prajapati, Brian M. Calimlim, Henrique D. Teixeira, Jiewei Zeng, Meng Liu, Jonathan I. Silverberg
#492 - Effects of Upadacitinib on Patient-Reported Symptoms of Atopic Dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) Results From Two Pivotal Phase 3 Studies (MEASURE UP 1 and MEASURE UP 2)
Jonathan I. Silverberg, Jacob P. Thyssen, David Rosmarin, Andrew E. Pink, Brian M. Calimlim, Henrique D. Teixeira, Xiaofei Hu, Yang Yang, Diamant Thaçi
#493 - Severity Strata For Atopic Dermatitis Symptom Scale (ADerm-Ss), Atopic Dermatitis Impact Scale (ADerm-Is), And Worst Pruritus Numerical Rating Scale
Jonathan I. Silverberg, Eric L. Simpson, Brian M. Calimlim, Xiaoran Li, Xiaowu Sun, Yael A. Leshem
#494 - Financial Burden and Impact of Atopic Dermatitis Out-Of-Pocket Healthcare Expenses Among Black Individuals in the United States
Raj Chovatiya, MD, PHD, Wendy Smith Begolka, MBS, Isabelle J. Thibau, MPH, Jonathan I. Silverberg, MD, PhD, MPH
#495 - Etrasimod, a novel, oral, selective sphingosine 1-phosphate receptor modulator, improves patient and clinician reported outcomes in adults with moderate-to-severe atopic dermatitis in a randomized, double-blind, placebo-controlled phase 2
Emma Guttman-Yassky, Robert Bissonette, Leon Kircik, Dedee Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahuluwalia, Jonathan Silverberg
#501 - The Multidimensional Burden of Moderate to Severe Atopic Dermatitis: A Pooled Analysis of Baseline Data from Three Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Jonathan I. Silverberg, Jacob P. Thyssen, Antonio Costanzo, Brian M. Calimlim, Allan R. Tenorio, Naijun Chen, Melinda J. Gooderham
#502 - Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: the Pivotal Phase 3 ADORING Clinical Program
Lawrence F. Eichenfield, MD, Jonathan I. Silverberg, MD, PhD, MPH, Robert Bissonnette, MD, Anna M. Tallman, PharmD, Philip M. Brown, MD, JD, David S. Rubenstein, MD, PhD, Stephen C. Piscitelli, PharmD, John E. Jett, PhD
#503 - Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials
Amy S. Paller, MD; Pedro Mendes-Bastos, MD; Lawrence F. Eichenfield, MD; Weily Soong, MD; Peter Lio, MD; Vimal H. Prajapati, MD; Andrew M. Platt, PhD; Henrique D. Teixeira, PhD; John Liu, MD; Barry Ladizinski, MD; Jacob P. Thyssen, MD
#504 - Skindex-Mini Performance in Pediatric Patients with Atopic Dermatitis
Anjani P. Sheth, BA, Alli J. Blumstein, BS, Stephanie M. Rangel, PhD, Amy S. Paller, MD